Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223

BACKGROUND: In men with metastatic castration‐resistant prostate cancer (mCRPC) with primarily bone metastases, radium‐223 ((223)Ra) improves overall survival (OS). However, the selection of (223)Ra is not guided by specific validated clinicopathologic factors, and thus outcomes are heterogeneous. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Al‐Ezzi, Esmail M., Alqaisi, Husam A., Iafolla, Marco A. J., Wang, Lisa, Sridhar, Srikala S., Sacher, Adrian G., Fallah‐Rad, Nazanin, Jiang, Di M., Watson, Geoffrey A., Catton, Charles N., Warde, Padraig R., Hamilton, Rob J., Fleshner, Neil E., Zlotta, Alexandre R., Hansen, Aaron R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419779/
https://www.ncbi.nlm.nih.gov/pubmed/34254464
http://dx.doi.org/10.1002/cam4.4125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419779/
https://www.ncbi.nlm.nih.gov/pubmed/34254464
http://dx.doi.org/10.1002/cam4.4125

Ejemplares similares